^
Association details:
| Biomarker: | AR mutation |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | tulmimetostat (DZR123) (EZH2 inhibitor, EZH1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2126 - Therapeutic potential of CPI-0209
Published date:
03/14/2021
Excerpt:
Thus, our results indicate that CPI-0209 may have the potential to be effective for AR-dependent mCRPC that are resistant to current AR inhibitors, supporting potential clinical development in mCRPC.